Thyroid, Kidney Cancer Drug Granted Orphan Drug Status for Hepatocellular Carcinoma
The U.S. Food and Drug Administration has granted orphan drug status to cabozantinib for the treatment of hepatocellular carcinoma, the most common type of liver cancer.